Increases in the molar chemotherapeutic-equivalent concentrations of gemcitabine-(C4-amide)-[anti-HER2/neu] created declines in the survival of chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) populations (Figures 4,7 and 8). This evidence concerns the gene ERBB2 and breast adenocarcinoma.